Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1996 1
1997 1
1998 2
1999 3
2000 4
2001 2
2002 7
2003 1
2004 2
2005 1
2006 13
2007 6
2008 9
2009 18
2010 18
2011 19
2012 20
2013 21
2014 22
2015 28
2016 32
2017 23
2018 19
2019 8
2020 10
2021 11
2022 9
2023 13
2024 15
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

293 results

Results by year

Filters applied: . Clear all
Page 1
A randomized, comparative, open-label study of efficacy and tolerability of alfuzosin, tamsulosin and silodosin in benign prostatic hyperplasia.
Manjunatha R, Pundarikaksha HP, Madhusudhana HR, Amarkumar J, Hanumantharaju BK. Manjunatha R, et al. Indian J Pharmacol. 2016 Mar-Apr;48(2):134-40. doi: 10.4103/0253-7613.178825. Indian J Pharmacol. 2016. PMID: 27127315 Free PMC article. Clinical Trial.
Because of their greater uroselectivity and minimal hemodynamic effects, alfuzosin, tamsulosin, and silodosin are generally preferred. The aim of this study was to compare the efficacy and tolerability of alfuzosin, tamsulosin, and silodosin in patients with BPH and …
Because of their greater uroselectivity and minimal hemodynamic effects, alfuzosin, tamsulosin, and silodosin are generally preferred …
Evolving Role of Silodosin for the Treatment of Urological Disorders - A Narrative Review.
Jindan L, Xiao W, Liping X. Jindan L, et al. Drug Des Devel Ther. 2022 Aug 26;16:2861-2884. doi: 10.2147/DDDT.S373659. eCollection 2022. Drug Des Devel Ther. 2022. PMID: 36051157 Free PMC article. Review.
Literature reveals that silodosin is beneficial in improving nocturia events related to LUTS/BPH. Silodosin exerts effect on relaxing muscles involved in detrusor obstruction, therefore prolonging the need for patients undergoing invasive surgery. ...Reports from Ph …
Literature reveals that silodosin is beneficial in improving nocturia events related to LUTS/BPH. Silodosin exerts effect on r …
Silodosin: a review of its use in the treatment of the signs and symptoms of benign prostatic hyperplasia.
Keating GM. Keating GM. Drugs. 2015 Feb;75(2):207-17. doi: 10.1007/s40265-014-0344-z. Drugs. 2015. PMID: 25575983 Review.
Silodosin was noninferior to tamsulosin in terms of improving LUTS associated with BPH. ...Silodosin was generally well tolerated and was associated with a low risk of orthostatic hypotension. ...
Silodosin was noninferior to tamsulosin in terms of improving LUTS associated with BPH. ...Silodosin was generally well tolera …
Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.
Jung JH, Kim J, MacDonald R, Reddy B, Kim MH, Dahm P. Jung JH, et al. Cochrane Database Syst Rev. 2017 Nov 22;11(11):CD012615. doi: 10.1002/14651858.CD012615.pub2. Cochrane Database Syst Rev. 2017. PMID: 29161773 Free PMC article. Review.
Silodosin versus alfuzosinBased on two studies with a total of 155 randomized participants, silodosin may or may not result in a clinically important increase in urologic symptom scores (MD 3.83, 95% CI 0.12 to 7.54; low-quality evidence). ...AUTHORS' CONCLUSIONS: …
Silodosin versus alfuzosinBased on two studies with a total of 155 randomized participants, silodosin may or may not result in …
Silodosin: a selective alpha1A-adrenergic receptor antagonist for the treatment of benign prostatic hyperplasia.
Schilit S, Benzeroual KE. Schilit S, et al. Clin Ther. 2009 Nov;31(11):2489-502. doi: 10.1016/j.clinthera.2009.11.024. Clin Ther. 2009. PMID: 20109995 Review.
OBJECTIVE: This article reviews the pharmacology, pharmacokinetics, clinical efficacy, adverse effects, drug interactions, and dosage and administration of silodosin in adult male patients with BPH. ...To determine whether silodosin's selectivity for t …
OBJECTIVE: This article reviews the pharmacology, pharmacokinetics, clinical efficacy, adverse effects, drug interactions, and dosage …
Comparative efficacy and safety of alpha-blockers as monotherapy for benign prostatic hyperplasia: a systematic review and network meta-analysis.
Yoosuf BT, Panda AK, Kt MF, Bharti SK, Devana SK, Bansal D. Yoosuf BT, et al. Sci Rep. 2024 May 15;14(1):11116. doi: 10.1038/s41598-024-61977-5. Sci Rep. 2024. PMID: 38750153 Free PMC article.
IPSS has been considerably improved by tamsulosin 0.4 mg, naftopidil 50 mg and silodosin 8 mg as compared to the placebo. Based on the p-score, tamsulosin 0.4 mg had the highest probability of ranking for IPSS, PVR, and Qmax, whereas doxazosin 8 mg had the highest probabil …
IPSS has been considerably improved by tamsulosin 0.4 mg, naftopidil 50 mg and silodosin 8 mg as compared to the placebo. Based on th …
Silodosin for benign prostatic hyperplasia.
Cantrell MA, Bream-Rouwenhorst HR, Hemerson P, Magera JS Jr. Cantrell MA, et al. Ann Pharmacother. 2010 Feb;44(2):302-10. doi: 10.1345/aph.1M320. Epub 2010 Jan 13. Ann Pharmacother. 2010. PMID: 20071497 Review.
OBJECTIVE: To review the pharmacology, pharmacokinetics, clinical trials, and safety of silodosin, a recently approved alpha(1A)-adrenergic receptor (AR) antagonist for benign prostatic hyperplasia (BPH). ...The usual dose of silodosin is 8 mg once daily and …
OBJECTIVE: To review the pharmacology, pharmacokinetics, clinical trials, and safety of silodosin, a recently approved alpha(1 …
The efficacy and safety of silodosin in treating BPH: a systematic review and meta-analysis.
Cui Y, Zong H, Zhang Y. Cui Y, et al. Int Urol Nephrol. 2012 Dec;44(6):1601-9. doi: 10.1007/s11255-012-0261-6. Epub 2012 Aug 24. Int Urol Nephrol. 2012. PMID: 22914879 Review.
Total international prostate symptom score (IPSS) (P=0.92 SWD=2.92 95% CI=2.19-3.65 the mean decrease of total IPSS was from 6.4 to 10.6), voiding symptom score, storage symptom score, and quality-of-life score indicated that silodosin was more effective than the placebo. …
Total international prostate symptom score (IPSS) (P=0.92 SWD=2.92 95% CI=2.19-3.65 the mean decrease of total IPSS was from 6.4 to 10.6), v …
Silodosin for Prevention of Ureteral Injuries Resulting from Insertion of a Ureteral Access Sheath: A Randomized Controlled Trial.
Kim JK, Choi CI, Lee SH, Han JH, Shim YS, Choo MS; Young Endourological Study group. Kim JK, et al. Eur Urol Focus. 2022 Mar;8(2):572-579. doi: 10.1016/j.euf.2021.03.009. Epub 2021 Mar 23. Eur Urol Focus. 2022. PMID: 33741297 Clinical Trial.
Silodosin prevented significant postoperative ureteral injury involving the smooth muscle layer more successfully than in the control group (9.3% vs 27.3%; p = 0.031). ...Silodosin premedication might be an effective and safe technique to replace prestenting. ...
Silodosin prevented significant postoperative ureteral injury involving the smooth muscle layer more successfully than in the control …
Silodosin: treatment of the signs and symptoms of benign prostatic hyperplasia.
Curran MP. Curran MP. Drugs. 2011 May 7;71(7):897-907. doi: 10.2165/11204780-000000000-00000. Drugs. 2011. PMID: 21568366 Review.
Silodosin is an alpha-adrenoceptor antagonist with high selectivity for alpha(1A)- relative to alpha(1B)- adrenoceptors. ...Long-term, open-label extension trials demonstrated that silodosin provided sustained relief of the signs and symptoms of BPH for up to 1 year …
Silodosin is an alpha-adrenoceptor antagonist with high selectivity for alpha(1A)- relative to alpha(1B)- adrenoceptors. ...Long-term …
293 results